Showing results (91-100 of 516) with videos related to
Sort By:
Pageof 52
Respirology (Carlton, Vic.)|April 9, 2009
Reduced exhaled breath condensate pH in asthmatic smokers using inhaled corticosteroidsBinita Kane, Zoe Borrill, Thomas Southworth, et al.International Journal of Chronic Obstructive Pulmonary Disease|June 6, 2017
Clinical characteristics of COPD patients with tidal expiratory flow limitationJames Dean, Umme Kolsum, Paul Hitchen, et al.Archivos De Bronconeumologia|August 20, 2025
Biological Therapy in COPD Management: Current Evidence, Challenges and OpportunitiesDave Singh, Antonio Menéndez Lobo, Andrew Higham, et al.ERJ Open Research|March 11, 2026
Increased alveolar tissue destruction in a sub-group of COPD patients with increased alveolar septal eosinophil countsAndrew Higham, Sophie Booth, Josiah Dungwa, et al.NPJ Primary Care Respiratory Medicine|June 17, 2016
Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary diseaseDave Singh, Massimo Corradi, Monica Spinola, et al.Current Opinion in Pulmonary Medicine|November 6, 2019
Small airway disease in chronic obstructive pulmonary disease: insights and implications for the clinicianDave Singh, Gabriella Long, José E D Cançado, et al.International Journal of Chronic Obstructive Pulmonary Disease|September 28, 2020
Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD - A Detailed AnalysisHenrik Watz, Kathleen Rickard, Tara Rheault, et al.International Journal of Chronic Obstructive Pulmonary Disease|September 14, 2012
Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trialKai M Beeh, Dave Singh, Lilla Di Scala, et al.American Journal of Respiratory and Critical Care Medicine|May 16, 2023
Serum IL-8 as a Determinant of Response to Phosphodiesterase-4 Inhibition in Chronic Obstructive Pulmonary DiseaseMirco Govoni, Michele Bassi, Debora Santoro, et al.International Immunopharmacology|November 14, 2025
Anti-oxidative and anti-inflammatory effects of the phosphodiesterase 3/4 inhibitor ensifentrineSimon Lea, Jian Li, Kieran Littolff, et al.Pageof 52